ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1359

New Markers for Celiac Disease: Anti-Neo-Epitope Human and Microbial Transglutaminases

Torsten Matthias1, Sandra Neidhöfer2, Patricia Jeremias1 and Aaron Lerner3, 1Aesku.Kipp.Institute, Wendelsheim, Germany, 2AESKU.KIPP.Stitute, Wendelsheim, Germany, 3B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: autoimmune diseases

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Microbial transglutaminase (mTg) and human tissue Tg (tTg) complexed to gliadin peptides present neo-epitopes. Antibodies against these complexes are called tTg neo-epitope and mTg neo-epitope. Reliability of antibodies against the non-complexed and complexed forms of both transglutaminases to reflect intestinal damage and to diagnose the pediatric Celiac Disease (PCD) was compared.

Methods: 95 PCD patients, 99 normal children (NC) and 79 normal adults (NA) were tested using the following ELISAs detecting IgA, IgG or both IgA+IgG combined: AESKULISA® tTg (tTg, RUO), AESKULISA® tTg New Generation (tTg neo-epitope (tTg-neo)), AESKULISA® mTg (RUO) and AESKULISA® mTg neo-epitope (mTg-neo, RUO). Marsh criteria were used for the degree of intestinal injury.

Results: All anti-mTg-neo and anti-tTg-neo levels were higher (p<0.001) compared to the single antigens. tTg-neo IgA and IgG+IgA were higher than mTg-neo IgA and IgA+IgG (p<0.0001). The antibody activities reflecting best the increased intestinal damage were: mTg-neo IgA> mTg-neo IgA+IgG > tTg-neo IgG ≥ mTg-neo IgG > tTg-neo IgA> tTg-neo IgA+IgG. Taken together, mTg-neo IgG and tTg-neo IgA & IgA+IgG correlated best with intestinal pathology (r=0.5633, r=0.6165 & r= 0.6492; p<0.0001, p<0.0001 & p<0.0001 respectively).

Conclusion: The complexed forms of both transglutaminases exhibited a higher OD activity and better reflected intestinal damage in PCD, compared to the non-complexed forms. mTg is immunogenic in children with CD and by complexing to gliadin its immunogenicity and pathology reflection is enhanced.


Disclosure: T. Matthias, None; S. Neidhöfer, None; P. Jeremias, None; A. Lerner, None.

To cite this abstract in AMA style:

Matthias T, Neidhöfer S, Jeremias P, Lerner A. New Markers for Celiac Disease: Anti-Neo-Epitope Human and Microbial Transglutaminases [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/new-markers-for-celiac-disease-anti-neo-epitope-human-and-microbial-transglutaminases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-markers-for-celiac-disease-anti-neo-epitope-human-and-microbial-transglutaminases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology